文献速递淋巴瘤

微小残留病状态可预测初治滤泡性淋巴瘤患者结局:III期GALLIUM研究的前瞻性分析

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
PubMed 文献 · J Clin Oncol · 2023-12-14

基于随机多中心III期GALLIUM试验,分析初治滤泡性淋巴瘤患者诱导化疗及维持治疗期间微小残留病(MRD)状态与结局的关系。MRD阳性与中期诱导和诱导结束时无进展生存期(PFS)更差相关,G-化疗较R-化疗的MRD应答率更高,MRD阴性是长期疾病控制的前提。

要点

  • 中期诱导MRD阳性者PFS显著更差(HR 3.03,95%CI 2.07-4.45,P<.0001)。
  • G-化疗较R-化疗在中期诱导(94.2% vs 88.9%)和诱导结束(93.1% vs 86.7%)的MRD应答率更高。
  • 维持治疗期间R组较G组MRD阳性率更高(R-CHOP 20.7% vs G-CHOP 7.0%;R-CVP 21.7% vs G-CVP 9.4%)。

核心结论

  • MRD状态可判断诱导后及维持治疗期间的结局,MRD阴性是滤泡性淋巴瘤长期疾病控制的前提。

研究设计与样本

  • 随机、多中心III期GALLIUM试验(NCT01332968)的前瞻性分析,纳入初治滤泡性淋巴瘤患者,诱导接受奥妥珠单抗(G)或利妥昔单抗(R)联合苯达莫司汀、CHOP或CVP化疗,缓解者以相同抗体维持。
  • 在预设时间点(中期诱导、诱导结束、维持及随访期间每4-6个月)评估MRD状态,诊断时有可评估生物标志物数据的患者纳入生存分析。

主要发现

  • 中期诱导MRD阳性与PFS更差相关(HR 3.03,95%CI 2.07-4.45,P<.0001),诱导结束时MRD阳性亦与PFS更差相关(HR 2.25,95%CI 1.53-3.32,P<.0001)。
  • 中期诱导MRD应答率G-化疗组94.2% vs R-化疗组88.9%(P=.013),诱导结束时G-化疗组93.1% vs R-化疗组86.7%(P=.0077)。
  • 晚期应答者(中期诱导阳性/诱导结束阴性)较早期应答者(中期诱导阴性/诱导结束阴性)PFS显著更差(HR 3.11,95%CI 1.75-5.52,P=.00011)。
  • 中期诱导时接受苯达莫司汀者MRD阳性比例最低(4.8% vs 接受CHOP者16.0%,P<.0001)。
  • 维持治疗期间R组较G组MRD阳性率更高(R-CHOP 20.7% vs G-CHOP 7.0%;R-CVP 21.7% vs G-CVP 9.4%),MRD阳性与临床复发相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier: NCT01332968) trial. PATIENTS AND METHODS: Patients received induction with obinutuzumab (G) or rituximab (R) plus bendamustine, or cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or cyclophosphamide, vincristine, prednisone (CVP) chemotherapy, followed by maintenance with the same antibody in responders. MRD status was assessed at predefined time points (mid-induction [MI], end of induction [EOI], and at 4-6 monthly intervals during maintenance and follow-up). Patients with evaluable biomarker data at diagnosis were included in the survival analysis. RESULTS: MRD positivity was associated with inferior progression-free survival (PFS) at MI (hazard ratio [HR], 3.03 [95% CI, 2.07 to 4.45]; P < .0001) and EOI (HR, 2.25 [95% CI, 1.53 to 3.32]; P < .0001). MRD response was higher after G- versus R-chemotherapy at MI (94.2% v 88.9%; P = .013) and at EOI (93.1% v 86.7%; P = .0077). Late responders (MI-positive/EOI-negative) had a significantly poorer PFS than early responders (MI-negative/EOI-negative; HR, 3.11 [95% CI, 1.75 to 5.52]; P = .00011). The smallest proportion of MRD positivity was observed in patients receiving bendamustine at MI (4.8% v 16.0% in those receiving CHOP; P < .0001). G appeared to compensate for less effective chemotherapy regimens, with similar MRD response rates observed across the G-chemo groups. During the maintenance period, more patients treated with R than with G were MRD-positive (R-CHOP, 20.7% v G-CHOP, 7.0%; R-CVP, 21.7% v G-CVP, 9.4%). Throughout maintenance, MRD positivity was associated with clinical relapse. CONCLUSION: MRD status can determine outcome after induction and during maintenance, and MRD negativity is a prerequisite for long-term disease control in FL. The higher MRD responses after G- versus R-based treatment confirm more effective tumor cell clearance.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pott C, Jurinovic V, Trotman J, et al. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study. J Clin Oncol. 2023. PMID: 38096461. doi:10.1200/JCO.23.00838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。